Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 5, 1997, Pages 531-543

  Cheng, Ching Ling ^b   Smith, David E ^a   Carver, Peggy L ^b   Cox, Steven R ^b   Watkins, Paul B ^b   Blake, Debbie S ^b   Kauffman, Carol A ^b   Meyer, Katherine M ^b   Amidon, Gordon L ^b   Stetson, Philip L ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DAPSONE; DELAVIRDINE; DRUG METABOLITE; ERYTHROMYCIN; IBUPROFEN; PARACETAMOL; ZIDOVUDINE;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG HALF LIFE; DRUG PROTEIN BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; STEADY STATE; TABLET;

ADMINISTRATION, ORAL; ADULT; ALKYLATION; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BREATH TESTS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DELAVIRDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; ERYTHROMYCIN; HIV SEROPOSITIVITY; HUMANS; INDOLES; LIVER; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; PIPERAZINES; PROTEIN BINDING; PROTEIN SYNTHESIS INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 12644270207     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90133-8     Document Type: Article

References (19)

1. Althaus IW, Chou JJ, Gonzales AJ, Deibel MR, Chou KC, Kezdy FJ, et al. Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J Biol Chem 1993;268:6119-24.
2. Campbell TB, Young RK, Eron JJ, D'Aquila RT, Tarpley WG, Kuritzkes DR. Evaluation of the bisheteroarylpiperazine reverse transcriptase inhibitor U-87201E in combination with zidovudine or didanosine against HIV-1 infection in vitro. J Infect Dis 1993;168:318-26.
3. Dornsife RE, St Clair MH, Huang AT, Panella TJ, Koszalka GW, Burns CL, et al. Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother 1991;35:322-8.
4. Dueweke TJ, Kezdy FJ, Waszak GA, Deibel MR, Tarpley WG. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem 1992;267: 27-30.
5. Romero DL, Busso M, Tan CK, Reusser F, Palmer JR, Poppe SM, et al. Non-nucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1991;88:8806-10.
6. Vasudevachari MB, Battista C, Lane HC, Psallidopoulos MC, Zhao B, Cook J, et al. Prevention of the spread of HIV-1 infection with non-nucleoside reverse transcriptase inhibitors. Virology 1992;190:269-77.
7. Althaus IW, Chou JJ, Gonzales AJ, Deibel MR, Chou KC, Kezdy FJ, et al. Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. Biochem Pharmacol 1994;47:2017-28.
8. Cox SR, Batts DH, Ward P, Freimuth WW, Staton BA, Peel BG, et al. Escalating single and multiple dose safety, tolerance and pharmacokinetics (PK) of delavirdine mesylate (DLV, U-90152S) in normal volunteers [abstract]. National Conference on Human Retroviruses and Related Infections, December 12-16,1993:158.
9. 3, who are maintained on a stable dose of AZT [abstract]. National Conference on Human Retroviruses and Related Infections, December 12-16, 1993:158.
10. Voorman RL, Maio SM, Wang X. Mechanism-based inactivation of rat and human cytochrome P450 3A by delavirdine. Ninth International Conference on Cytochrome P450, Zurich, Switzerland, July 23-27, 1995.
11. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G,et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-606.
12. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450: studies in rats and patients. J Clin Invest 1989;83:688-97.
13. Turgeon DK, Leichtman AB, Lown KS, Normolle DP, Deeb GM, Merion RM, et al. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 1994;56:253-60.
14. Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA. Alterations in gastric acidity in patients with human immunodeficiency virus. Clin Infect Dis 1995; 21:1431-8.
15. Dressman JB. Comparison of canine and human gastrointestinal physiology. Pharm Res 1986;3:123-31.
16. Mojaverian P, Vlasses PH, Parker S, Warner C. Influence of single and multiple doses of oral ranitidine on the gastric transit of an indigestible capsule in humans. Clin Pharmacol Ther 1990;47:382-8.
17. Staton BA, Johnson MG, Friis JM, Adams WJ. Simple, rapid and sensitive high-performance liquid Chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. J Chromatogr B 1995;668:99-106.
18. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore: Williams & Wilkins, 1995.
19. Tozer TN, Gambertoglio JG, Furst DE, Avery DS, Holford NHG. Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans. J Pharm Sci 1983; 72:1442-6.